NRG1 and ovarian cancer: Secondly, seribantumab—a monoclonal antibody that blocks HER3 activation by NRG1—led to the inhibition of NRG1 fusion-dependent tumor growth in patient-derived breast, lung, and ovarian cancer models [100].